ArticleInternational journal of general medicine2022
Significant Biomarkers Identification Associated with Cutaneous Squamous Cell Carcinoma Progression.
Article in International journal of general medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- TK1 in gastric cancer: Helicobacter pylori-driven oncogenesis biomarker, utility, and emerging targeted therapies.Frontiers in oncology · 2026Review
- Electrochemical and Optical Carbon Dots and Glassy Carbon Biosensors: A Review on Their Development and Applications in Early Cancer Detection.Micromachines · 2025Review
- Strategic approaches in oral squamous cell carcinoma diagnostics using liquid biopsy.Periodontology 2000 · 2024Review
- Utilizing systems genetics to enhance understanding into molecular targets of skin cancer.Experimental dermatology · 2024Review
- Targeting receptor tyrosine kinase signaling: Avenues in the management of cutaneous squamous cell carcinoma.iScience · 2023Review
- Review
- Implication of Amyloid Precursor-like Protein 2 Expression in Cutaneous Squamous Cell Carcinoma Pathogenesis.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to identify significant genes associated with cutaneous squamous cell carcinoma (CSCC) initiation and development. Methods: The overlapped differential expressed genes (DEGs) between normal and CSCC samples were firstly screened out, followed by KEGG analysis. The top 10 hub genes were then detected from the whole protein-protein interaction (PPI) network. Further, important biomarkers continuously associated with actinic keratosis (AK), CSCC, and CSCC invasion was successively filtrated. GSEA analysis was finally performed to reveal potential mechanisms associated with biomarkers. Results: A total of 179 DEGs were identified, which were enriched in pathways in cancer, PI3K-Akt signaling pathway, and human papillomavirus infection. The 10 hub genes were firstly identified from the PPI network, and they were all highly expressed in AK tissues compared with normal tissues. Next, we found that 6 genes were overexpressed in CSCC compared with AK tissues. Further, we identified that the expression of 2 genes (MYBL2 and TK1) was higher in CSCC invasion groups compared with samples without invasion. Through a series of filtrations, we confirmed that MYBL2 and TK1 were the most significant biomarkers associated with CSCC initiation and progression. The pan-cancer analysis further supported their prognostic value in human cancers. GSEA analysis found that they positively correlated with N glycan biosynthesis and p53 signaling pathways. Conclusion: MYBL2 and TK1 were proved to play a vital role in CSCC tumorigenesis and progression, which may act as promising biomarkers or therapeutic targets for accurate diagnosis and treatment of CSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.